Acquisition of CB Fleet drives up Prestige OTC
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
“Continued strong consumption levels” across its portfolio, plus the acquisition of CB Fleet last year, helped push up sales at Prestige Brands’ North American OTC Healthcare unit by 20.5% to US$869 million (€738 million) in the 12 months ended 31 March 2018, reported the firm’s chief executive officer Ron Lombardi.